Compare CMCT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMCT | AKTX |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1M | 11.5M |
| IPO Year | 1996 | 2014 |
| Metric | CMCT | AKTX |
|---|---|---|
| Price | $0.56 | $5.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | ★ 13.3M | 218.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $116,669,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.06 | $0.12 |
| 52 Week High | $14.41 | $5.50 |
| Indicator | CMCT | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 78.95 |
| Support Level | $0.06 | $0.45 |
| Resistance Level | $0.85 | $5.50 |
| Average True Range (ATR) | 0.19 | 0.48 |
| MACD | 0.10 | 0.18 |
| Stochastic Oscillator | 21.69 | 93.22 |
Creative Media & Community Trust Corp is a Maryland corporation and REIT. It mainly acquires, develops, owns, and operates both multifamily properties situated in vibrant communities throughout the United States and Class A and creative office real assets in markets with similar business and employment characteristics to multifamily investments. All of its communities are located in areas that include traditional downtowns and suburban main streets, which have high barriers to entry, high population density, positive population trends, and a propensity for growth. Currently, the company consists of three types of commercial real estate properties, namely office, hotel, and multifamily.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.